Use of quetiapine as an add on therapy in the treatment of post traumatic stress disorder
Study identifier:AU-SEA-0006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A multicentre, parallel group, randomised, double blind, placebo controlled study of the use of quetiapine as an add on therapy in the treatment of post traumatic stress disorder
Medical condition
Post-Traumatic Stress Disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine Fumarate, quetiapine fumarate placebo
Sex
All
Actual Enrollment
90
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Dec 2004
Primary Completion Date: 01 Sept 2007
Study Completion Date: 01 Aug 2008
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Placebo Seroquel + existing therapy | Drug: quetiapine fumarate placebo oral 0 mg Other Name: n/a |
| Experimental: 2 Seroquel + existing therapy | Drug: Quetiapine Fumarate oral flexible dose Other Name: Seroquel |
Contacts
Investigators
Principal Investigator
AstraZeneca Australia Medical Director
AstraZeneca
